A completed Phase 1b/2 interventional trial evaluated the anti-HER2 bispecific antibody zanidatamab combined with docetaxel in HER2-positive breast cancer, and with tislelizumab plus chemotherapy (capecitabine/oxaliplatin) in HER2-positive gastric or gastroesophageal junction adenocarcinoma. The study assessed safety, tolerability, pharmacokinetics, and preliminary antitumor activity across both tumor types.
BeiGene has completed a Phase 1b/2 interventional trial (NCT04276493) examining zanidatamab—a bispecific antibody targeting two distinct HER2 epitopes—in combination regimens for advanced HER2-positive malignancies. The trial enrolled participants across two distinct cohorts: those with HER2-positive breast cancer receiving zanidatamab plus docetaxel, and those with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma receiving zanidatamab combined with the PD-1 inhibitor tislelizumab and chemotherapy (capecitabine plus oxaliplatin).
Zanidatamab's bispecific design enables simultaneous binding to the HER2 extracellular domains II and IV, a mechanism intended to enhance receptor downregulation and antibody-dependent cellular cytotoxicity beyond what monospecific HER2-targeted agents achieve. Pairing this agent with cytotoxic chemotherapy and, in the gastric/GEJ cohort, checkpoint inhibition represents a multimodal approach to HER2-driven tumor suppression in a setting where prognosis remains poor despite existing targeted therapies.
Primary endpoints included safety and tolerability characterization alongside pharmacokinetic profiling, with preliminary antitumor activity as a key secondary objective. Full efficacy and safety results from this completed trial have not been detailed in the available registry data, and formal publication of outcomes is pending.
Key points
- Zanidatamab is a bispecific anti-HER2 antibody that simultaneously targets HER2 epitopes II and IV, distinguishing it mechanistically from trastuzumab and pertuzumab.
- The breast cancer cohort evaluated zanidatamab plus docetaxel; the gastric/GEJ cohort evaluated zanidatamab with tislelizumab, capecitabine, and oxaliplatin.
- The Phase 1b/2 trial (NCT04276493) has been completed; detailed efficacy and safety data have not yet been publicly reported.
- Both HER2-positive breast cancer and gastric/GEJ adenocarcinoma represent high-unmet-need indications where novel HER2-directed combinations are under active investigation.
- The trial was sponsored by BeiGene and assessed pharmacokinetics alongside antitumor activity as part of its endpoints.
Why it matters
Zanidatamab's dual-epitope HER2 targeting offers a mechanistically differentiated approach in HER2-amplified solid tumors, and completion of this combination trial may inform future registrational strategies in both breast and gastric/GEJ adenocarcinoma. Results will be relevant to oncologists managing patients who have progressed on or are ineligible for standard HER2-directed regimens.